<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210663</url>
  </required_header>
  <id_info>
    <org_study_id>M14-489</org_study_id>
    <nct_id>NCT02210663</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the tolerability, safety, pharmacokinetics and
      preliminary efficacy of single agent Veliparib in Japanese subjects with advanced solid
      tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities of veliparib</measure>
    <time_frame>During the first cycle (28 days) of veliparib administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in participant physical exam measurements</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Blood pressure, pulse and body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in participant clinical lab results</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Hematology, Chemistry and Urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Collect all adverse events at each visit and assess according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary tumor response</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 8 months.</time_frame>
    <description>According to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>For 24 hours following veliparib dosing.</time_frame>
    <description>Maximum observed concentration, occurring at Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to Cmax (peak time, Tmax)</measure>
    <time_frame>For 24 hours following veliparib dosing.</time_frame>
    <description>The time at which maximum plasma concentration (Cmax) is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>For 24 hours following veliparib dosing.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>veliparib (ABT-888)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veliparib (ABT-888)</intervention_name>
    <description>Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.</description>
    <arm_group_label>veliparib (ABT-888)</arm_group_label>
    <other_name>veliparib</other_name>
    <other_name>ABT-888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed malignant solid tumor, and any of the
             following: * Subjects with recurrent high grade serous ovarian cancer who completed or
             discontinued platinum based therapy; * Subjects with BRCA-mutated breast cancer who
             have received prior chemotherapy with anthracycline and/or taxanes; * Subjects with
             deleterious mutations of BRCA with advanced solid tumors who have received available
             standard therapies.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Life expectancy of greater than 12 weeks.

          -  Adequate organ and marrow functionÂ· Measurable or non-measurable disease.

        Exclusion Criteria:

          -  Major surgery and/or radiation within (&lt;) 4 weeks prior to study enrollment.

          -  Chemotherapy or hormone therapy within (&lt;) 4 weeks prior to study enrollment except
             for mitomycin C and nitrosoureas, in which case it is 6 weeks.

          -  Any investigational agents within (&lt;) 4 weeks prior to study enrollment.

          -  Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study
             enrollment.

          -  Toxicities (with the exception of alopecia) from prior major surgery, radiation, or
             systemic chemotherapy have not recovered to less than grade 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hideyuki Hashiba, BS</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie GK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128056</name>
      <address>
        <city>Hidaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129976</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128057</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5.</citation>
    <PMID>28665051</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>PARP</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <keyword>Fallopian tube</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>veliparib</keyword>
  <keyword>ABT-888</keyword>
  <keyword>BRCA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

